Infectious diseases are the major cause of rising burden in disease management market. Such diseases are communicable from one individual to another. It can be transferred either by direct contact or indirect methods. These diseases are transmitted by numerous infectious agents such as bacteria, fungi, virus, nematodes, and parasites. Such diseases can be prevented through anti-infective drugs, which include antifungal, antiviral drugs, antibacterial and antiparasitic. These diseases include malaria, tuberculosis, HIV, influenza, and hepatitis. Several leading players associated with healthcare industry are introducing numerous innovative and advanced technologies to offer effective treatment options, diagnosis solutions, antimicrobial therapy, and vaccination.
According to AVERT, a UK based international HIV and aids charity organization, in 2015, approximately 6.5 million people were infected with Human Immunodeficiency Virus (HIV) in the west and central African region and around only 28% of the individuals who are HIV infected were able to access antiretroviral therapy. HIV is one of the top 10 causes of the death and major concern. According to World Health Organisation (WHO) report published in 2018, around 1 million individuals died from HIV in 2016 worldwide.
According to World Health Organisation (WHO) report published in February 2018, around 10.4 million people suffered from Tuberculosis (TB) worldwide in 2016 and is one of the major reasons for death globally. Most of the TB deaths are occurring in low and middle-income countries.
European Centre for Disease Prevention and Control (ECDC), in February 2018, published that around 44,000 individuals are dying from lung diseases linked with seasonal influenza in Europe annually.
The rising incidences of infectious diseases and growing geriatric population are the major factors that are driving the market. Furthermore, accessibility and availability of treatment and diagnosis of these diseases and rising prevalence of cancer disease are attributed to boost the growth of the market. Government organizations are investing in research and development to find out more innovative solutions to these diseases. Awareness program initiative started by various organizations towards these conditions has anticipated the growth of the market. Furthermore, the entrance of generic drug companies providing arrays of solutions is expected to propel the growth.
However, accessibility of a large number of fake drugs may impede the market expansion. In addition, low adoption of treatments owing to lack of awareness among patients about alternative effective solution available in the market may hamper the growth of the market. On the other hand, rising technology advancements which include point of care diagnostics treatment, wearable smart sensing devices, agglutination assays in the rapid diagnosis of various infectious diseases providing effective treatment plan is positively affecting the market and providing the opportunity for the continuous market expansion.
Geographically, the market can be segmented into North America, Europe, Asia- Pacific and LAMEA. North America is expected to be dominant in this market attributed to factors including rising incidences of such disorders and rising number of clinical laboratories for the development of new drugs. Moreover, the presence of developed healthcare infrastructure, increasing funding activities to support the development new advanced solution of these diseases and growing percentage of treatment are the major factors that are expected to further boost the market growth.
Asia- Pacific is expected to be the fastest growing market owing to factors including high disposable incomes, the high prevalence of these diseases in emerging region and growing investment in the diagnosis of these diseases. Moreover, several organizations have come forward as a charity organization to provide the treatment and diagnosis of infectious diseases and spreading awareness. For example, World’s leading healthcare company, Novartis is supplying free drugs to those patients who are suffering from malaria in Africa.
Major Key players in the market are GlaxoSmithKline plc., BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH., Merck & Co., Inc., Novartis AG, Janssen Pharmaceutical, Inc., and Gilead Sciences.
Several prominent players are launching new products for the advanced treatment of infectious diseases. For example, in May 2017, a global healthcare company, Merck has received Food and Drug Administration (FDA) approval for its new product ISENTRESS HD, a new 1200 mg inhibitor for HIV-1 infected individuals. This drug is also useful in combination therapy with other therapies.
Moreover, in January 2017, BioCryst Pharmaceuticals, Inc. has received Health Canada approval for its newly launched drug RAPIVAB for the patients who are infected with influenza.
• By Mode of Treatment
• By Disease Indication
• By Drug Class
• By End User
o Hospital Pharmacy
o Retail Pharmacy
• Regions Covered:
o North America (U.S and Canada)
o Europe (Germany, France, Italy and Rest of Europe)
o Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
o LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)